Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects

British Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2008, Pages 660-666

  Lim, Kyoung Soo ^a   Cho, Joo Youn ^a   Jang, In Jin ^a   Kim, Bo Hyung ^a   Kim, Jaewoo ^a   Jeon, Ji Young ^a   Tae, Yu Mi ^a   Yi, Sojeong ^a   Eum, Soyoung ^a   Shin, Sang Goo ^a   Yu, Kyung Sang ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

CYP2D6; Drug interaction; Flecainide; Paroxetine; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; FLECAINIDE; PAROXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 55149095948     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03267.x     Document Type: Article

References (25)

1. Sachse C, Brockmoller J, Bauer S, Root I. Cytochrome p450 2d6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 60 : 284 95.
2. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 23 37.
3. Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, Spear BB, Katz DA. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004 14 : 279 84.
4. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000 67 : 567 76.
5. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007 25 : 3837 45.
6. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainde in relation to the sparteine/ debrisoquine metabolizer phenotype. Br J Clin Pharmacol 1989 28 : 555 66.
7. 3M Pharmaceuticals. 3M product information: Tambocor™. Available at http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=1423&type= display (last accessed: 25 September 2007).
8. Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984 53 : 89B 94B.
9. Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M, Jaillon P. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994 55 : 256 69.
10. Munafo A, Buclin T, Tuto D, Biollaz J. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur J Clin Pharmacol 1992 43 : 441 3.
11. Birgersdotter UM, Wong W, Turgeon J, Roden DM. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992 33 : 275 80.
12. Doki K, Homma M, Kuga K, Kusano K, Watanabe S, Yamaguchi I, Kohda Y. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2006 62 : 919 26.
13. Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005 33 : 845 52.
14. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006 34 : 563 9.
15. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999 9 : 669 82.
16. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1999 47 : 450 3.
17. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmoller J, Oellerich M. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit 2006 28 : 673 7.
18. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjovist F, Bertilsson L. Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995 5 : 159 64.
19. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006 31 : 1274 85.
20. Tenneze L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002 72 : 112 22.
21. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991 1 : 143 8.
22. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008 83 : 234 42.
23. Boriani G, Strocchi E, Capucci A, Calliva R, Frabetti L, Ambrosioni E, Magnani B. Flecainide: evidence of non-linear kinetics. Eur J Clin Pharmacol 1991 41 : 57 9.
24. Nogales Asensio JM, Moreno Sanchez N, Doncel Vecino LJ, Villar Mariscal C, Lopez-Minguez JR, Merchan Herrera A. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity. Int J Cardiol 2007 114 : E65 7.
25. Thevenin J, Da Costa A, Roche F, Romeyer C, Messier M, Isaaz K. Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol 2003 26 : 1907 8.